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The  hematopoietic  precursor  of thymocytes  (prothymocyte)  is  a  specialized 
cell, committed to thymocyte differentiation and discrete from both the already 
characterized  precursors of B  cells  and the pluripotential  stem cell  (1-3).  We 
have developed a quantitative assay for this cell and have previously used it to 
explore the kinetics of repopulation of the murine thymus aRer 7-irradiation (4) 
and to establish that prothymocytes are found among the null cell population of 
both the spleen and bone marrow.  They may be distinguished from other cells 
in this population since  they bear  surface  antigens  reactive  with  rabbit  anti- 
mouse brain  antisera  and can  be  induced to display  characteristic  thymocyte 
differentiation antigens (5, 6). The physical and surface properties of these cells 
have permitted  us to obtain populations which are enriched  40-fold.  Prepara- 
tions of precursors from bone marrow contain the enzyme terminal deoxyribo- 
nucleotidyl transferase  (Tdt) while those from spleen lack this activity. 
Materials and Methods 
Mice-Source and Care.  Female mice, 5-6 wk old, were obtained from The Jackson Labora- 
tory, Bar Harbor, Maine. (hereafter designated as AKR/J) and Cumberland View Farms, Clinton, 
Tenn. (AKR/Cumberland, hereafter designated as AKR/C). AKR/J mice bear the Thy 1.1 (~AKR) 
alloantigen, while AKR/C anomalously bear Thy 1.2 (0C3H)  (7). 
Antisera and Complement.  Anti-Thy 1 antisera were produced by the reciprocal immunization 
of AKR/J and  AKR]C  mice with thymocytes.  The preparation  of these  sera  as well  as  rabbit 
antisera to mouse brain and mouse Ig has been described previously (4). 
Rabbit serum selected for low toxicity to mouse thymocytes was used as a source of complement 
in alloantiserum-mediated cytotoxicity; guinea pig serum was used as a  complement source  in 
heteroantiserum-mediated killing. 
Origin  of Cells Repopulating the  Thymus.  The assay  for cells capable of repopulating the 
thymuses of irradiated mice has been described in detail (2). Thymocytes derived from the injected 
cells are identified by a cytotoxic test making use of the difference in Thy 1 antigens in AKR mice 
purchased from different sources.  AKR/C  (Thy  1.2)  mice are  injected with hematopoietic cells 
from AKR/J (Thy 1.1) mice. The proportion of cells in the regenerating thymus which bear the 
donor type Thy 1 antigen is determined by selectively killing the thymocytes bearing one of the 
two Thy 1 alleles and measuring residual [3H]TdR incorporation. 
To facilitate comparison of the activity of the various populations tested,  their repopulation 
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activity  was  measured.  This  was  defined  as  the  number  of cells  required  to  produce  10% 
repopulation of AKR/C thymus with ALR/J derived thymocytes 14 days after transfer and was 
calculated by dividing the number of cells injected by the percentage of cells of donor origin found 
( ×  10). 
Cell Preparation,  The  procedure  for  inducing  the  appearance  of thymic  alloantigens  with 
thymopoietin and the techniques for separating cells on discontinuous gradients of bovine serum 
albumin  (BSA),  eliminating  Thy  1  or  mouse  immunoglobulin-positive  cells  and  depleting 
complement receptor-jpositive lymphocytes have all been described in detail (2, 6, 8). 
Terminal Deoxyribonucleotidyl  Transferase.  (EC  2.7.7.31  deoxyribonucleoside triphosphate: 
DNA nucleotidyl exotransferase; terminal transferase) was assayed in preparations after homog- 
enization and partial purification by phosphocellulose chromatography  as described by Kung et 
al. (8), with 2.5 gg oligo (dA 12-18) obtained from P-L Biochemicals, Inc., Milwaukee, Wis. as an 
initiator. The polymerization was followed by measuring the incorporation of [3H]dG (supplied as 
the  triphosphate,  sp  act  12  Ci/mM)  into  trichloroacetic  precipitable  material.  [3H]dGTP  was 
purchased from New England Nuclear Corp., Boston, Mass.  1 U of enzyme activity is the amount 
which catalyzes the incorporation of 1 nmol of deoxynucleotide monophosphate into acid insoluble 
material in 1 h. 
The soluble material  obtained  between  4  x  107  and  109  nucleated cells was  applied to each 
phosphocellulose column. The activity in each cell population was calculated by integrating the 
activity found in all enzymatically active fractions. The two peaks of activity described by Kung 
et al. were not calculated separately. 
Results 
Isolation ofProthymocytes.  Spleen cells or bone marrow cells, suspended in 
RPMI-1640  and  7 mg/ml  BSA are  initially  separated  by flotation on either  a 
single step BSA or Ficoll-Hypaque density gradient.  The least dense third  of 
the initial  spleen cell preparation  is used for the subsequent purification.  The 
population accumulating at the interface is removed, suspended at a concentra- 
tion  of 107/ml,  and  incubated  sequentially  with  rabbit  antiserum  to  mouse 
immunoglobulin  and  guinea  pig complement,  and then  anti-Thy  1 antiserum 
and  rabbit  complement.  The  cells  are  then  pelleted  by  centrifugation  and 
resuspended in warm  (37°C) isotonic Tris-buffered ammonium chloride (ACT). 
This step was originally introduced to remove erythrocytes (10). We find that it 
consistently removes a population of nucleated cells and increases the efficiency 
of the next step in removing dead or damaged cells.  After 10 min in ACT the 
cells are diluted five-fold with cold (4°C) medium and passed through  a  glass 
wool column.  The  eluted cells are  again  pelleted  and  resuspended  at  107/ml. 
Complement receptor  (CR) positive cells which escaped the  anti-Ig treatment 
are  removed  and  a  further  separation  on  the  basis  of density  achieved  by 
flotation in a  discontinuous gradient of BSA. The cells accumulating at the 25 
and  27%  interfaces  are  pooled,  washed,  and  tested  for  their  prothymocyte 
activity. 
Examples of the results achieved by using this procedure are shown in Table 
I. Also included are the proportion of cells in each fraction which become Thy 1 
positive after thymopoietin treatment.  The degree of enrichment  of the induc- 
ible  cells  directly  paralleled  that  of the  thymus-repopulating  activity.  The 
starting  materials  used here were suspensions  of cells from  10 wk old female 
AKR/J mice.  The  results  are representative  of many other experiments  with 
young adult mice. The degree of enrichment achieved does vary with the age of 
the mice used for the experiments  and the greatest repopulation  activity was 
obtained  when  spleen  cells  from  weanling  mice  were  used  (0.08  ×  l0  s cells 
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TABLE  I 
Enrichment of  Prothymocytes 
1845 
Fraction  Recovery* of  Repopulation$  Degree of  Tp§ induc- 
cells  activity  enrichment  ible 
% 
S-I  Unfractionatod  spleen  5.0 x l0  s  7 0  x los  1  ND][ 
S-If  Hypaque-Ficoll  1.5 x i0  a  3.4  x los  2.1  ND 
S-III  Anti-Ig +  Anti-Thy 1  4.0 x  l0  w  1.I  ×  los  6.4  [1)¶ 
S-IV  ACTTreatod  2.6 ×  l0  T  0.81 x  los  8.8  15) 
S-V  Glass wool filtered  1.0 x  107  0.39 ×  l0  s  17.5  15 
S-VI  CRL Depleted[[  2.3 ×  los  0.23 x  106  30.4  27 
BSA Gradient 
M-I  Unfractionated BM  1.8 ×  los  1.20 x  l0  s  1  ND 
M-II  Hypaque-Ficoll  9.2 ×  10  ~  0.66 ×  los  1.8  ND 
M-III  Anti-Ig and anti-Thy 1  4.8 ×  107  0.58 x  l0  s  2.1  (6) 
M-IV  ACT Treated  4.1 x  10  ~  0.52 ×  l0  s  2,3  11 
M-V  Glass wool filtered  1.3 x  107  0.25 ×  los  4.8  21 
M-VI  CRL Depleted  4.0 ×  10  ~  0.11 ×  los  10.9  46 
BSA Gradient 
* Viable cells  corrected for  sampling losses. 
* Number of  cells  required to produce  10% repopulation of  AKR/C thymus with AKR/T derived thymocytes 14 days after 
transfer. 
§ The percentage of  cells  rendered susceptible  to a-Thy 1.1 antiserum by incubation with thymopeietin. This is  calculated 
by subtracting the pe~entage killed  by this  serum in a control  sample of  cells  (not  treated with thymopoietin)  from the 
percentage of  cells  killed  in  a thymopoietin-treated  sample. A total  of  200 cells  was counted for  each determination. The 
results shown are the average of  duplicates. In similar experiments the coefficient  of  variation for  the determination  of 
inducible cells  is 22~e. Due to the small number of inducible cells  present no attempt was made to estimate these cells 
until the Thy 1.1-positive  cells  present in the bond marrow and spleen cell  preparations had been eliminated by treat- 
ment with anti-Thy  1.2 serum. 
I]  CRL, complement receptor lymphocyte;  ND, not done 
¶ Because of  the statistical  problems inherent m  counting small numbers of  cells  we regard only values greater than 10% 
as significant.  The parentheses indicate  results  which do not meet this  criterion. 
Terminal Deoxyribonucleotidyl Transferase in Prothymocyte Enriched Frac- 
tions.  Bollum  (10)  has  described  an  enzyme  with  the  unusual  property  of 
adding deoxyribonucleotides to a DNA primer in the absence of a template. The 
principal source is the thymus, where it is found in cortical thymocytes (12, 13). 
Peripheral  T  cells  lack  the  enzyme.  Low concentrations  are  found  in  bone 
marrow (14, 9). No other tissue has detectable activity. Although no function is 
known  for this  enzyme,  Baltimore  (14)  has  pointed  out that  it  is a  potential 
somatic mutator and could thus be implicated in the generation of immunologic 
diversity. 
Table  II  shows  that  the  population  of bone  marrow  cells  obtained  as  a 
consequence of preparing  fractions enriched  in prothymocytes is substantially 
(12-fold)  enriched in terminal transferase.  The degree of enrichment  is propor- 
tional to the extent of the purification of the precursor cells. This prothymocyte- 
rich fraction consists of Thy 1-negative cells. The majority of the Tdt-containing 
cells in the fractions are killed by rabbit antiserum against mouse brain (Table 
II, line 3). We have previously shown this serum to be cytolytic for thymocyte 
precursors (2). In three separate experiments with unfractionated bone marrow 
the  reduction  in  the  specific enzymatic  activity of the  surviving  cells varied 
from 68 to 83%.  Neither increasing the antibody concentrations nor subjecting 
the  surviving  cells  to  a  second  antibody  treatment  eliminated  the  residual 
activity. 
No transferase was found in any preparation  from spleen cells including one 
40-fold enriched in prothymocyte activity (Table II, line 5), nor was any activity 
detectable in  18-day fetal liver or spleen  (data not shown).  Mixing spleen cells 1846  BASCH  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE II 
Terminal Deoxyribonucleotidyl Transferase Activity of 
Prothymocyte Fractions 
Fraction  Activity 
Untreated bone marrow 
Prothymocyte-rich  fraction* 
Anti-mouss brain treated$ prothymocyte-rich fraction 
Normal rabbit serum treated§ prothymocyta-rich fraction 
Prothymocyte-rich fractionll  from spleen 
unitsH O D  cells 
0.16 
1.91 
0.35 
1.78 
0.01 
* Cells obtained from a BSA gradient aRer the prior removal of both glass wool adherent Thy 
1.1 and Ig-bearing ceils.  3.6 ~<  10  ° bone marrow cells from 105 AKR/J mice were fractionated 
to yield 1.6 × I0  ~  cells in the prethymocyte-enriehed fraction. IEquivalent to fraction M-VI in 
Table I). 
Cells from the prothymocyte-rich fraction treated with rabbit anti-mouse brain and guinea 
pig complement. Dead  ceils were removed by centrifugation over Hypaque-Ficoll. Live cells, 
which accumulated at the interface were washed twice before homogenization. 
§ Cells from the prothymocyte-rich fraction treated with normal rabbit serum and guinea pig 
complement and prepared as above. 
II Cells obtained from a BSA gradient after the removal of glass wool adherent, Thy 1.1, and Ig 
bearing  cells.  8.3  x  10  j  spleen  cells  were  fractionated  to  yield  4.3  x  107  cells  in  the 
prothymocyte-enriehed fraction. This fraction had a thymic precursor activity 37 times that of 
the starting population. (Equivalent to fraction S-VI m Table D. 
with thymocytes did not interfere significantly with the assay of the 
the thymocytes. 
enzyme in 
Discussion 
The  procedures  described  here  permit  the  partial  purification  of the  cells 
responsible for the repopulation of the thymus after irradiation.  They are based 
on the facts that the precursors are relatively low density cells, nonadherent to 
glass  wool,  and  resistant  to  the  cytotoxic effects of anti-Thy  1  and  anti-Ig 
antisera  (2). The entire sequence requires about 4 h and results in a 30-40-fold 
enrichment of the precursors from spleen. The procedure can also be applied to 
bone marrow cells but only a  10-15-fold enrichment is obtained with these cells. 
As expected, both precursor cells and thymopoietin-sensitive cells are purified 
together.  Previous  work  had  indicated  that  thymopoietin  inducible  cells 
can  serve  as  thymocyte  precursors  (16).  The  lesser  degree  of  purification 
achieved with bone marrow is a  consequence of both the paucity of Ig-positive 
and  Thy  1-positive cells  and  the  greater  number  of low density  cells  in  the 
marrow. 
The procedures which lead to the enrichment  of the bone marrow precursor 
also lead to the partial  purification of cells which contain the enzyme deoxyri- 
bonucleotidyl  transferase.  This  enzyme  is  present  in  high  concentrations  in 
thymic lymphocytes and it is reasonable to assume that it is also present in the 
precursor  cells.  Such an  association  is also suggested by the  susceptibility of 
both Tdt  containing  cells and  prothymocytes to cytolysis by antisera  against 
mouse  brain.  Tdt  has  also  been  found  in  the  precursor  cells  which  display 
thymic  alloantigens  after  treatment  with  thymopoietin  or  endotoxin  (17). 
Although this is strong evidence that terminal transferase is associated with a 
prothymocyte in  the  bone marrow,  difficult and  intriguing  questions remain BASCH  ET  AL.  BRIEF  DEFINITIVE  REPORT  1847 
unanswered. If the enzyme is present in prothymocytes, why can no enzyme be 
found in populations obtained from spleen or fetal liver? The splenic precursor 
is otherwise indistinguishable from the bone marrow-derived cell and the assay 
for transferase is sufficiently sensitive to detect 1% of the amount found in bone 
marrow.  Furthermore,  irradiated mice repopulated with Tdt-negative spleen 
cells  have  Tdt-positive  thymocytes.  R.  S.  Basch,  A.  V.  Hoffbrand,  and  K. 
Ganeshaguru, unpublished results. 
We  have  considered  a  variety  of  possibilities  to  explain  this  apparent 
heterogeneity. In the simplest, the assumption is made that the precursors only 
express the enzyme in the bone marrow environment. Either the induction of 
previously negative cells by the marrow environment, or the accumulation of 
enzyme-positive cells  by  that  environment,  would  account  for the  apparent 
heterogeneity.  In  either  case  we  would  argue  that  the  precursors  are  Tdt 
negative for most of their existence and only acquire the enzyme in the last 
stages of their prethymic development. 
The distribution could also result from a  negative influence exerted in the 
spleen, suppressing enzyme expression in cells which would otherwise contain 
it.  The splenic environment of normal mice does appear to be inimical to the 
expression of the thymus leukemia (TL) antigen which, like Tdt, is essentially 
restricted to thymocytes (18). 
More  complicated models  are  required  if the  heterogeneity in  Tdt content 
actually reflects specialization of the precursor pool.  It is plausible that some of 
the diverse T-cell subsets could arise from progenitors who differed from each 
other in the time at which they acquired or lost Tdt.  Furthermore, some Tdt 
containing bone marrow cells cannot be induced to display thymic alloantigens 
(17) and are thus presumably not in the T-cell lineage. If terminal transferase- 
mediated  somatic  mutation is  to  be  considered  as  a  source  of immunologic 
diversity, the enzyme should appear at some stage of the development of B-cell 
progenitors.  Perhaps  these  are  the  other  Tdt  containing cells  of the  bone 
marrow. 
Summary 
A  method  has  been  developed  for  the  enrichment  of the  hematopoietic 
precursors  of thymocytes from spleen  and  bone  marrow cells.  Up  to  40-fold 
enrichments were obtained resulting in preparations  in which as  few as  l0  s 
cells produced prompt repopulation of the thymus of an irradiated mouse. 
Precursor cells from bone  marrow appear to contain the enzyme terminal 
deoxyribonucleotidyl transferase  (Tdt),  an  agent  suggested  as  a  potential 
somatic  mutator.  This  enzyme  (Tdt)  was  not  detectable  in  any  spleen  cell 
preparation examined, including one in which a  40-fold enrichment of thymo- 
cyte precursors had been produced. This is the first difference reported between 
the splenic and bone marrow precursors of thymocytes. 
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